Browsing Scopus İndeksli Yayınlar Koleksiyonu by Subject "6 Inhibitors"
Now showing items 1-1 of 1
-
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
(FUTURE MEDICINE LTD, 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...